Cardiovascular Journal of Africa: Vol 27 No 3 (May/June 2016)

CARDIOVASCULAR JOURNAL OF AFRICA • Volume 27, No 3, May/June 2016

AFRICA

133

pressure before the development of nosocomial acute kidney injury.

Nephrol Dial Transplant

2009;

(2): 504–511.

28. Sutton TA, Fisher CJ, Molitoris BA. Microvascular injury and dysfunc-

tion during ischemic acute renal failure.

Kidney Int

2002;

: 1539–1549.

29. Imai E, Abe K. Blood pressure drop in summer may cause acute kidney

injury with irreversible reduction of glomerular filtration rate.

Clin Exp

Nephrol

2013;

(1): 1–2.

30. Hsu CY, Ordonez JD, Chertow GM, Fan D, McCulloch CE, Go AS.

The risk of acute renal failure in patients with chronic kidney disease.

Kidney Int

2008;

(1): 101–107.

31. Benowitz NL. Cigarette smoking and cardiovascular disease: patho-

physiology and implications for treatment.

Prog Cardiovasc Dis

2003;

: 91–111.

32. Heiss C, Amabile N, Lee AC,

et al

. Brief secondhand smoke exposure

depresses endothelial progenitor cells activity and endothelial function:

sustained vascular injury and blunted nitric oxide production.

J Am Coll

Cardiol

2008;

: 1760–1771.

33. Flouris AD, Vardavas CI, Metsios GS, Tsatsakis AM, Koutedakis Y.

Biological evidence for the acute health effects of secondhand smoke

exposure.

Am J Physiol

2009;

298

: L3–12.

34. Alonso-Coello P, Bellmunt S, McGorrian C,

et al

. American College

of Chest Physicians: antithrombotic therapy in peripheral artery

disease: antithrombotic therapy and prevention of thrombosis, 9th edn:

American College of Chest Physicians evidence-based clinical practice

guidelines.

Chest

2012;

141

(2 Suppl): e669S–690S.

35. Wu VC, Huang TM, Lai CF,

et al.

Acute-on-chronic kidney injury at

hospital discharge is associated with long-term dialysis and mortality.

Kidney Int

2011;

(11): 1222–1230.

Confidence Through Clinical

and Real World Experience

1-3

Millions of Patients Treated Across Multiple Indications

#1 NOAC prescribed by Cardiologists

References:

Patel M.R., Mahaffey K.W., Garg J.

et al.

Rivaroxaban versus warfarin in non-valvular atrial fibrillation.

N Engl J Med

. 2011;365(10):883–91.

Tamayo S., Peacock W.F., Patel M.R.,

et al.

Characterizing major bleeding in patients with nonvalvular atrial fibrillation: A pharmacovigilance study of 27 467 patients taking rivaroxaban.

Clin Cardiol

. 2015;38(2):63–8.

Camm A.J., Amarenco P., Haas S.

et al.

XANTUS: A Real-World,

Prospective, Observational Study.

Calculation based on IMS Health MIDAS, Database: Monthly Sales December 2015.

For fullprescribing information,refer to thepackage insertapprovedby theMedicinesRegulatoryAuthority (MCC). S4 XARELTO

10 (Film-coated tablets)

.Reg.No.

:42/8.2/1046.Eachfilm-coated tabletcontainsrivaroxaban10mg.

PHARMACOLOGICALCLASSIFICATION:

A.8.2Anticoagulants.

INDICATION:

Prevention of venous thromboembolism (VTE) in patients undergoing major orthopaedic surgery of the lower limbs. S4 XARELTO

15 and XARELTO

20 (Film-coated tablets). Reg. No.: XARELTO

15: 46/8.2/0111; XARELTO

20: 46/8.2/0112. Each film

coated tablet contains rivaroxaban 15 mg (XARELTO

15) or 20 mg (XARELTO

20).

PHARMACOLOGICAL CLASSIFICATION:

A.8.2 Anticoagulants.

INDICATIONS:

(1) Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (SPAF); (2)

Treatment of deep vein thrombosis (DVT) and for the prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE); (3) Treatment of pulmonary embolism (PE) and for the prevention of recurrent pulmonary embolism (PE) and deep vein thrombosis (DVT).

HCR:

Bayer (Pty) Ltd, Reg. No.: 1968/011192/07, 27 Wrench Road, Isando, 1609. Tel: 011 921 5044 Fax: 011 921 5041.

L.ZA.MKT.GM.01.2016.1265

*Impact RX Data Oct - Dec 2015

NOAC: Non Vitamin K Oral Anticoagulant